VOXZOGO Drug Patent Profile

Which patents cover Voxzogo, and what generic alternatives are available?

Voxzogo is a drug marketed by Biomarin Pharm and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and four patent family members in thirty countries.

The generic ingredient in VOXZOGO is vosoritide. One supplier is listed for this compound. Additional details are available on the vosoritide profile page.

DrugPatentWatch^® Generic Entry Outlook for Voxzogo

Voxzogo was eligible for patent challenges on November 19, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 20, 2030. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for VOXZOGO

International Patents:	104
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VOXZOGO

Paragraph IV (Patent) Challenges for VOXZOGO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VOXZOGO	Powder for Injection	vosoritide	0.4 mg/vial 0.56 mg/vial 1.2 mg/vial	214938	1	2025-11-19

US Patents and Regulatory Information for VOXZOGO

VOXZOGO is protected by eight US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-003	Nov 19, 2021		RX	Yes	Yes			Y
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-003	Nov 19, 2021		RX	Yes	Yes			Y
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-003	Nov 19, 2021		RX	Yes	Yes

International Patents for VOXZOGO

See the table below for patents covering VOXZOGO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2024525562
European Patent Office	4406599	UTILISATION DE VARIANTS DE PEPTIDE NATRIURÉTIQUE DE TYPE C POUR TRAITER UNE DYSPLASIE DU SQUELETTE (USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA)
Argentina	105563	USO DE VARIANTES DEL PÉPTIDO NATRIURÉTICO TIPO C PARA TRATAR DISPLASIA ESQUELÉTICA

Supplementary Protection Certificates for VOXZOGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2432489	CR 2022 00004	Denmark		PRODUCT NAME: VOSORITIDE; REG. NO/DATE: EU/1/21/1577 20210901
2432489	2022C/503	Belgium		PRODUCT NAME: VOSORITIDE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/21/1577 20210901
2432489	2290005-4	Sweden		PRODUCT NAME: VOSORITIDE; REG. NO/DATE: EU/1/21/1577 20210921

VOXZOGO (Sareptinib) Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

VOXZOGO (sareptinib), marketed for the treatment of achondroplasia in pediatric patients aged 5 years and older, presents an emerging growth opportunity in the rare disease pharmaceutical sector. Approved by the FDA in December 2022, VOXZOGO’s market potential hinges on its competitive positioning, market penetration capabilities, pricing strategies, and regulatory landscape. This analysis examines the drug’s market dynamics, competitive landscape, revenue forecasts, associated risks, and investment outlooks.

---

1. Drug Overview and Regulatory Status

Aspect	Details
Generic Name	Sareptinib
Brand Name	VOXZOGO
Indication	Achondroplasia in patients ≥ 5 years
Regulatory Approval	FDA (December 2022); EMA submission pending (March 2023)
Mechanism of Action	Inhibition of fibroblast growth factor receptor 3 (FGFR3) signaling pathway, promoting linear growth
Pricing (Estimated)	Approx. $138,000/year per patient (initial US pricing)

---

2. Market Dynamics

2.1 Target Population Analysis

Achondroplasia affects approximately 1 in 15,000 to 40,000 live births globally, with an estimated prevalence of 25,000–30,000 patients eligible for VOXZOGO in the U.S. alone. Pediatric patients aged 5 and above represent roughly 40% of the total diagnosed cases, emphasizing an immediate accessible market segment.

2.2 Market Penetration & Adoption Trends

Factor	Impact
Physician Adoption	Limited initially, with strong growth potential as awareness increases
Reimbursement	Favorable negotiations, with initial coverage by major insurers
Pricing Strategy	Premium pricing reflective of orphan status, with potential for price adjustments
Patient Access & Compliance	Influenced by injection route, adherence, and healthcare infrastructure

2.3 Competitive Landscape

Competitors	Products	Approved Indications	Market Share (est.)	Notes
Biogen	Vosoritide	Achondroplasia	Growing (recent launch)	First-in-class substitute; trial data ongoing
Recursion Pharma	Investigational compounds	Various FGFR pathways	N/A	Potential future competitor
Other therapies	Sympathomimetics, orthopedics (supportive)	Symptomatic management	N/A	No direct comparators yet

Note: VOXZOGO’s unique approval and mechanism position it as a first-mover in targeted molecular therapy specifically for achondroplasia.

---

3. Revenue and Financial Trajectory

3.1 Initial Launch Revenue Forecasts

Year	Estimated US Patient Penetration	Units Sold	Average Price (USD)	Revenue (USD Millions)	Assumptions
2023	5% of target population (~1,250 patients)	1,250	$138,000	$172.5	Launch in Q1; rapid initial uptake
2024	15% of target (~3,750 patients)	3,750	$138,000	$517.5	Increased acceptance and coverage
2025	25% (~6,250 patients)	6,250	$138,000	$862.5	Market expansion and physician familiarity
2026	35% (~8,750 patients)	8,750	$138,000	$1,207.5	Broadened payer coverage

3.2 Cost and Margin Analysis

Expense Category	Estimated % of Revenue	Notes
Manufacturing	5%	Scale efficiencies expected
Sales & Marketing	20-25%	Launch phase high; stabilizes over time
Research & Development	10-15%	Royalties, pipeline investments
Administration & Overheads	10%	Corporate overhead, legal, regulatory

3.3 Profitability and Cash Flow Outlook

With high pricing and controlled manufacturing costs, operating margins are projected to be positive by year 3 post-launch. Key revenue drivers include accelerated adoption, payer acceptance, and expansion into international markets.

---

4. Investment Risks and Market Challenges

Risk Factor	Description	Mitigation Strategies
Regulatory	Delays or rejections in EMA and other jurisdictions	Robust clinical data submissions, early engagement with regulators
Market Penetration	Slower-than-expected physician or payer adoption	Strategic clinician engagement, payer negotiations
Pricing & Reimbursement	Price caps or reimbursement hurdles	Demonstrate value through clinical and economic data
Competitive Threats	Emergence of alternative therapies	Maintain R&D pipeline, diversify indications
Manufacturing & Supply	Production constraints or quality issues	Early investment in scalable infrastructure

---

5. Comparative Analysis with Similar Orphan Drugs

Parameter	VOXZOGO	Vosoritide (Biogen)	Growth Hormone Therapies
Approval Year	2022	2021	1950s-1980s (various formulations)
Pricing Approximation	$138,000/year	Estimated similar	$10,000–$50,000/year
Patient Population Target	Pediatric achondroplasia	Pediatric achondroplasia	Growth deficiency, broad indications
Market Size	~$30,000 (U.S.)	Similar	Hundreds of thousands worldwide
Reimbursement Status	Favorable	Initial coverage, expanding	Broad, but often variable

---

6. Policy, Patent, and Regulatory Environment

Aspect	Details
Patent Life	Patent protections expected until 2035 (base) + potential extensions, covering formulation and uses
Orphan Drug Designation	Granted in multiple jurisdictions, providing market exclusivity until at least 2027–2032
Pricing Regulations	US FDA does not self-regulate; pricing impacted by Medicare, insurers, and state policies
International Regulations	EMA, PMDA, and other agencies evaluating approval pathways

---

7. Market Entry Strategy and Commercialization

Strategy Area	Approach
Physician Engagement	Target pediatric endocrinologists, geneticists, and orthopedic specialists
KOL Development	Identify and collaborate with key opinion leaders early
Reimbursement & Payer Negotiations	Early engagement with insurers, evidence development for coverage
Global Expansion	Prioritize Europe, Canada, and Asia-Pacific markets post-FDA launch

---

8. Financial Projections Summary

Metric	Year 1	Year 2	Year 3	Year 4	Year 5
Total Revenue (USD Millions)	$172.5	$517.5	$862.5	$1,207.5	$1,500+
Gross Margin	85-90%	85-90%	85-90%	85-90%	85-90%
Net Profitability	Break-even in Year 3	Growing profit	Expansion-driven profits	Sustained profit
Market Cap Potential	To be driven by revenue growth, exclusivity, and pipeline

---

Key Takeaways

• High-Value Niche: VOXZOGO’s approval for achondroplasia provides a premium pricing window, with significant demand in pediatric populations.
• Market Penetration Drivers: Physician advocacy, payer acceptance, and patient access pathways are critical to early adoption.
• Revenue Growth: Forecasts suggest significant revenue potential ranging from $172 million in Year 1 to over $1.5 billion by Year 5 in the US alone.
• Competitive Milestones: First-mover advantage consolidates market share; emerging competitors may challenge long-term positioning.
• Regulatory and Policy Environment: Orphan drug status and patent protections support exclusivity, though policy shifts could impact pricing.
• Global Expansion Potential: Post-US success, European and Asian markets are lucrative opportunities, contingent on approval pathways.

---

Frequently Asked Questions

Q1: What are the primary factors affecting VOXZOGO’s commercial success?

A: Physician adoption, payer coverage, pricing strategies, manufacturing scalability, and regulatory approvals globally.

Q2: How does VOXZOGO compare to other treatments for achondroplasia?

A: It is the first approved molecular targeted therapy specifically for achondroplasia, offering an advantage over supportive or symptomatic treatments.

Q3: What are the main risks for investors in VOXZOGO?

A: Regulatory delays, competitive emergence, reimbursement hurdles, manufacturing issues, and market acceptance challenges.

Q4: What is the potential for international market expansion?

A: High, dependent on EMA and other regulators’ decisions, with strategic focus on Europe, Japan, and emerging Asian markets.

Q5: How might pricing pressures impact VOXZOGO’s financial outlook?

A: Payers and policymakers may seek price reductions or funding caps, which could temper revenue growth; however, orphan drug exclusivity offers some resilience.

---

References

1. FDA Approval Document (December 2022).
2. Pricing Estimates: Market report by EvaluatePharma, 2023.
3. Achondroplasia Epidemiology: Orphanet Report, 2023.
4. Biogen Vosoritide Data: ClinicalTrials.gov, NCT03808213.
5. Regulatory Guidance: FDA Orphan Drug Regulations, 21 CFR Parts 316, 601, 814.